Biosimilar medicines clinical use: an experience based-EU perspective

Adrian van den Hoven

13 July 2017
Washington D.C., USA
“Over the last 10 years, the EU monitoring system for safety concerns has not identified any difference in the nature, severity or frequency of adverse effects between biosimilars and their reference medicine.”

1 Medicines for Europe information based on EMA Post-authorisation Safety Update Reports (PSURs)
2 EMA – European Commission: Biosimilars in the EU – Information guide for healthcare professionals, 2017 (link)
### Change in # of treatment days
(2016 vs. year before biosimilar entrance)

<table>
<thead>
<tr>
<th>Medication</th>
<th>Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epoetin</td>
<td>+66%</td>
</tr>
<tr>
<td>G-CSF (filgrastim)</td>
<td>+122%</td>
</tr>
<tr>
<td>Growth hormone (somatropin)</td>
<td>+41%</td>
</tr>
<tr>
<td>Anti-TNF (infliximab &amp; etanercept)</td>
<td>+19%</td>
</tr>
<tr>
<td>Fertility (follitropin alfa)</td>
<td>+16%</td>
</tr>
<tr>
<td>Insulins</td>
<td>+19%</td>
</tr>
</tbody>
</table>

Source: QuintilesIMS (2017) The Impact of Biosimilar Competition in Europe
THE BENEFITS OF BIOSIMILAR MEDICINES

LAUNCH OF BIOSIMILAR MEDICINES

REDUCTION OF TREATMENT COST

MORE PATIENTS TREATED
MORE TREATMENT OPTIONS
MORE AUTONOMY TO PRESCRIBE
MORE INVESTMENT FOR:

HOSPITAL INFRASTRUCTURE

CAPACITY BUILDING

HEALTHCARE SERVICES

IMPROVED CARE AND HEALTH OUTCOMES FOR PATIENTS

ENSURED SUPPLY CHAIN SECURITY
References (1)

What you need to know about biosimilar medicinal products
European Commission, 2013
(link)

What I need to know about biosimilar medicines – Information for patients
European Commission, 2016
(link)

Biosimilars in the EU – Information guide for healthcare professionals
EMA, 2017
(link)

The impact of biosimilar competition in Europe
QuintilesIMS, 2017
(link)
Biosimilar regulation in the EU (link) Kurki & Ekman, Review of Clinical Pharmacology 2015

In support of the European Union biosimilar framework (link) Schneider et al, Nature Biotechnology 2012

Biosimilars: what clinicians should now (link) Weise et al, Blood 2012

Is there a reason for concern or is it just hype? A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars (link) Inotai et al, Expert Opinion on Biological Therapy 2017

Interchangeability of biosimilars: A European perspective (link) Kurki et al. Biodrugs 2017

The safety of switching between therapeutic proteins (link) Ebbers et al. Expert Opinion on Biological Therapy 2012


Biosimilar infliximab In inflammatory bowel disease: Outcomes of a managed switching programme (link) Razanskaite et al. Journal of Crohn’s and Colitis 2017

Delivering on the potential of biosimilar medicines (link) IMS Institute 2016

Biosimilars: a position paper of the European Society for Medical Oncology (ESMO), with particular reference to oncology prescribers (link) Tabernero et al. ESMO Open 2017